Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan

作者：Ming Wang, Qing Wu, Wanzhou Xu, Bin Qiao, Jingwei Wang, Hongyun Zheng, Shupeng Jiang, Junchi Mei, Zegang Wu, Yayun Deng, Fangyuan Zhou, Wei Wu, Yan Zhang, Zhihua Lv, Jingtao Huang, Xiaoqian Guo, Lina Feng, Zunen Xia, Li Di, Zhiliang Xu, Tiangang Liu, Pingan Zhang, Yongqing Tong, Yan Li · 发表于：medRxiv · 年份：2020 · DOI：10.1101/2020.02.12.20022327 · 被引用次数：164 · 研究领域：SARS-CoV-2 and COVID-19 Research、SARS-CoV-2 detection and testing、COVID-19 Clinical Research Studies

Summary Background 2019-Novel coronavirus (2019-nCoV) outbreaks create challenges for hospital laboratories because thousands of samples must be evaluated each day. Sample types, interpretation methods, and corresponding laboratory standards must be established. The possibility of other infections should be assessed to provide a basis for clinical classification, isolation, and treatment. Accordingly, in the present study, we evaluated the testing methods for 2019-nCoV and co-infections. Methods We used a fluorescence-based quantitative PCR kit urgently distributed by the Chinese CDC to detect 8274 close contacts in the Wuhan region against two loci on the 2019-nCoV genome. We also analyzed 613 patients with fever who underwent multiple tests for 13 respiratory pathogens; 316 subjects were also tested for 2019-nCoV. Findings Among the 8274 subjects, 2745 (33.2%) had 2019-nCoV infection; 5277 (63.8%) subjects showed negative results in the 2019-nCoV nucleic acid test (non-2019-nCoV); and 252 cases (3.0%) because only one target was positive, the diagnosis was not definitive. Eleven patients who originally had only one positive target were re-examined a few days later; 9 patients (81.8%) were finally defined as 2019-nCoV-positive, and 2 (18.2%) were finally defined as negative. The positive rates of nCoV-NP and nCovORF1ab were 34.7% and 34.7%, respectively. nCoV-NP-positive only and nCovORF1ab-positive cases accounted for 1.5% and 1.5%, respectively. In the 316 patients with mu...